These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 38041540)
1. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy. Yu B; Luo J; Yang Y; Zhen K; Shen B J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540 [TBL] [Abstract][Full Text] [Related]
2. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184 [TBL] [Abstract][Full Text] [Related]
3. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer. Zhang J; Zhang M; Tian Q; Yang J Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794 [TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer. Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558 [TBL] [Abstract][Full Text] [Related]
5. A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer. Qiu P; Guo Q; Pan K; Chen J; Lin J Front Oncol; 2022; 12():890242. PubMed ID: 36276158 [TBL] [Abstract][Full Text] [Related]
6. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer. Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247 [TBL] [Abstract][Full Text] [Related]
7. A novel fatty-acid metabolism-based classification for triple negative breast cancer. Yang X; Tang W; He Y; An H; Wang J Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837 [TBL] [Abstract][Full Text] [Related]
8. Genomic and Immunological Characterization of Pyroptosis in Lung Adenocarcinoma. Song Y; Qu Z; Feng H; Xu L; Xiao Y; Zhao Z; Wu D; Sun C; Fan X; Zhou D J Oncol; 2022; 2022():6905588. PubMed ID: 35938142 [TBL] [Abstract][Full Text] [Related]
9. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer. Cao T; Huang M; Huang X; Tang T PeerJ; 2024; 12():e16935. PubMed ID: 38435998 [TBL] [Abstract][Full Text] [Related]
10. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer. Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934 [TBL] [Abstract][Full Text] [Related]
11. Characterization of Pyroptosis-Related Subtypes Li C; Pan J; Jiang Y; Wu Y; Jin Z; Chen X Front Genet; 2022; 13():788670. PubMed ID: 35386285 [TBL] [Abstract][Full Text] [Related]
12. Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer. Luo L; Wei Q; Xu C; Dong M; Zhao W Front Immunol; 2022; 13():933703. PubMed ID: 36189269 [TBL] [Abstract][Full Text] [Related]
13. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer. Shen X; Zhong J; He J; Han J; Chen N Front Immunol; 2022; 13():978092. PubMed ID: 36105819 [TBL] [Abstract][Full Text] [Related]
14. Identification of Pyroptosis-Relevant Signature in Tumor Immune Microenvironment and Prognosis in Skin Cutaneous Melanoma Using Network Analysis. Zhu Y; Han D; Duan H; Rao Q; Qian Y; Chen Q; Du X; Ni H; Wang S Stem Cells Int; 2023; 2023():3827999. PubMed ID: 36818162 [TBL] [Abstract][Full Text] [Related]
15. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer. Liu Z; Ding M; Qiu P; Pan K; Guo Q Front Immunol; 2023; 14():1200282. PubMed ID: 37520534 [TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization and Establishment of a Prognostic Model Based on Primary Immunodeficiency Features in Association with RNA Modifications in Triple-Negative Breast Cancer. Xia H; Xu X; Guo Y; Deng X; Wang Y; Fu S Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38136994 [TBL] [Abstract][Full Text] [Related]
17. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs. Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K Front Immunol; 2022; 13():982486. PubMed ID: 36119101 [TBL] [Abstract][Full Text] [Related]
18. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy. Zhou Y; Che Y; Fu Z; Zhang H; Wu H Front Public Health; 2022; 10():902378. PubMed ID: 35875026 [TBL] [Abstract][Full Text] [Related]
19. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer. Li XF; Fu WF; Zhang J; Song CG BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369 [TBL] [Abstract][Full Text] [Related]
20. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma. Yan C; Niu Y; Li F; Zhao W; Ma L J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]